Beam Therapeutics Inc (BEAM) Stock to return to profitability in the near future

JP Morgan raised the price target for the Beam Therapeutics Inc (NASDAQ:BEAM) stock from “a Neutral” to “an Overweight”. The rating was released on January 29, 2024, according to finviz. The research report from Jefferies has downgraded the stock from Buy to Hold, with a price target set at $30. The stock was downgraded by […]

Beam Therapeutics Inc (BEAM) Stock is the one stock you should own forever

JP Morgan raised the price target for the Beam Therapeutics Inc (NASDAQ:BEAM) stock from “a Neutral” to “an Overweight”. The rating was released on January 29, 2024, according to finviz. The research report from Jefferies has downgraded the stock from Buy to Hold, with a price target set at $30. The stock was downgraded by […]

Why Beam Therapeutics Inc (NASDAQ:BEAM) Stock climbed 8.38% in Last Three Months?

JP Morgan raised the price target for the Beam Therapeutics Inc (NASDAQ:BEAM) stock from “a Neutral” to “an Overweight”. The rating was released on January 29, 2024, according to finviz. The research report from Jefferies has downgraded the stock from Buy to Hold, with a price target set at $30. The stock was downgraded by […]

Beam Therapeutics Inc (BEAM) Stock is more thoughtful than you think

JP Morgan raised the price target for the Beam Therapeutics Inc (NASDAQ:BEAM) stock from “a Neutral” to “an Overweight”. The rating was released on January 29, 2024, according to finviz. The research report from Jefferies has downgraded the stock from Buy to Hold, with a price target set at $30. The stock was downgraded by […]

Beam Therapeutics Inc (BEAM) Stock: Pessimism is a stepping stone to opportunity

JP Morgan raised the price target for the Beam Therapeutics Inc (NASDAQ:BEAM) stock from “a Neutral” to “an Overweight”. The rating was released on January 29, 2024, according to finviz. The research report from Jefferies has downgraded the stock from Buy to Hold, with a price target set at $30. The stock was downgraded by […]

Beam Therapeutics Inc (BEAM) Stock to return to profitability in the near future

JP Morgan raised the price target for the Beam Therapeutics Inc (NASDAQ:BEAM) stock from “a Neutral” to “an Overweight”. The rating was released on January 29, 2024, according to finviz. The research report from Jefferies has downgraded the stock from Buy to Hold, with a price target set at $30. The stock was downgraded by […]